Lycosome Oral Drug Delivery

 

Liver Targeting Delivery

 

clinical Phase IIa pharmacodynamic data:

  • LycoStatin – potentiated liver-targeting delivery statin with new anti-oxLDL mode of action
  • WP-Lycosome – anti-inflammatory peptide / small protein targeting liver inflammation

Both products have clinical Phase IIa pharmacodynamic data.

READ MORE

Cholesterol Crystal Disruption

 

pharmacokinetic and pharmacodynamic data:

  • GA-Lct-40 – targeting vulnerable atherosclerotic plaque

Proof-of-concept clinical efficacy data

 
  • ID-LctBP-20 – anti-hypertensive,
  • ID-LctPR-40 – anti-hypoxia for prostate hyperplasia, adjuvant cancer treatment
  • GAL – anti-infective for persistent, chronic forms of Chlamydia infection
  • T-RSV-Lycosome – diabetic foot ulcer regeneration

Monoclonal Antibody Therapy – pre-clinical

 

Monoclonal antibody, LycoMab, can be used as a vector to deliver and potentiate efficacy of pro-apoptotic lycopene to prostate cancer cells.

LycoStent(TM) - pre clinical

 

New class of molecules for prevention of restenosis of endovascular stents and vascular scaffolding.

Download LycoStent™ PDF

LYCOTEC NEWSLETTER

Subscribe now and receive publications newsletter from us!

 
 

© 2010 – 2018 Copyright Lycotec Limited. Registered in England and Wales No: 6527761.